Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer
Summary
The purpose of this pilot study is to look at the potential effects of paricalcitol (a drug similar to vitamin D) and nivolumab on pancreatic tumors in patients who are treated with gemcitabine and abraxane. The study will also look at the safety of including paricalcitol and nivolumab as part of the gemcitabine and abraxane chemotherapeutic regimen.
General Information
NCT#: NCT03519308
Study ID: UPCC 22217
Trial Phase: Pilot
Trial Sponsor: University of Pennsylvania Abramson Cancer Center
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Nivolumab, Paricalcitol